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Abstract
Background: The pathogenesis of idiopathic Parkinson's disease (PD) remains elusive, although
evidence has suggested that neuroinflammation characterized by activation of resident microglia in
the brain may contribute significantly to neurodegeneration in PD. It has been demonstrated that
aggregated  α-synuclein potently activates microglia and causes neurotoxicity. However, the
mechanisms by which aggregated α-synuclein activates microglia are not understood fully.
Methods: We investigated the role of prostaglandin E2 receptor subtype 2 (EP2) in α-synuclein
aggregation-induced microglial activation using ex vivo, in vivo and in vitro experimental systems.
Results:  Results demonstrated that ablation of EP2(EP2-/-) significantly enhanced microglia-
mediated ex vivo clearance of α-synuclein aggregates (from mesocortex of Lewy body disease
patients) while significantly attenuating neurotoxicity and extent of α-synuclein aggregation in mice
treated with a parkinsonian toxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Furthermore,
we report that reduced neurotoxicity by EP2-/- microglia could be attributed to suppressed
translocation of a critical cytoplasmic subunit (p47-phox) of NADPH oxidase (PHOX) to the
membranous compartment after exposure to aggregated α-synuclein.
Conclusion: Thus, it appears that microglial EP2 plays a critical role in α-synuclein-mediated
neurotoxicity.
Background
Increasing evidence has suggested that neuroinflamma-
tion may contribute significantly to neurodegeneration in
parkinsonian animals or even human Parkinson's disease
(PD) [1-3]. One of the key features of neuroinflammation
is microglial activation with resultant morphological
changes, increased expression of cell surface receptors,
and production of neurotrophic as well as neurotoxic fac-
tors [4]. The mechanisms underlying microglial activation
in parkinsonian animal models or in human PD are
largely unknown. Potential activators include environ-
mental toxicants, e.g. rotenone and 1-methyl-4-phenyl-
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1,2,3,6-tetrahydropyridine (MPTP) [5,6], as well as
endogenous substances, e.g. neuromelanin [7] More
recently, we have demonstrated that aggregated α-synu-
clein, a major component of Lewy bodies in PD and asso-
ciated synucleinopathies [8] potently activates microglia,
leading to dopaminergic (DAergic) toxicity in part
through activation of a membrane-associated nicotina-
mide adenine dinucleotide phosphate (NADPH) oxidase
(PHOX) [9].
The processes involved in microglial activation and PHOX
activation following aggregated α-synuclein exposure,
however, are largely unknown. One clue to the relation-
ship between microglial phagocytosis of protein aggre-
gates and subsequent microglial activation comes from
our recent investigation, where microglial activation
induced by aggregated amyloid β (Aβ) is altered when a
receptor for a prostaglandin E2  (EP2) is removed by
genetic ablation. The results suggest that microglia derived
from EP2-/- mice appear to have increased capacity for
clearance of Aβ peptides from tissue sections of patients
with Alzheimer's disease (AD) via phagocytosis without
the increased microglial-mediated paracrine neurotoxicity
induced by Aβ [10]. Given that PGE2, a product derived
from arachidonic acid by cyclooxygenase (COX) and spe-
cific synthases, is also significantly elevated in the sub-
stantia nigra (SN) and cerebrospinal fluid of PD patients
[11], in this study we investigated whether EP2 played any
role in the formation or handling of aggregated α-synu-
clein, events critically important in the pathogenesis of
PD. This was achieved by using complementary
approaches, including ex vivo experiments with human
tissue, in vivo experiments with the parkinsonian toxicant
MPTP, and finally in vitro experiments with purified
microglia exposed to aggregated α-synuclein. Our results
clearly demonstrated that microglial EP2 contributed to
α-synuclein aggregation and associated neurotoxicity as
well as microglial activation.
Methods
Materials
All chemicals were purchased from Sigma-Aldrich (St.
Louis, MO) unless stated otherwise. α-Synuclein and neu-
ronal nuclei (NeuN) antibodies were from Chemicon
(Temecula, CA); CD11b was from Serotec (Raleigh, NC);
p67-phox and p47-phox antibodies were from BD Bioscience
(San Diego, CA). Alexa fluorescent-labeled secondary
antibodies were from Molecular Probes (Eugene, OR).
4,6-Diamidino-2-phenylindole (DAPI)-containing
mounting medium was from Vector Laboratories (Burlin-
game, CA). Papain and DNase I were from Worthington
Biochemical (Lakewood, NJ). Culture media, heat-inacti-
vated fetal bovine serum, and penicillin/streptomycin
were from Invitrogen (Carlsbad, CA). Purified human α-
synuclein was from r-Peptide (Athens, GA)
Ex vivo studies
Frozen human mesocortex tissue from patients with Lewy
body disease was used as a source of physiologically aggre-
gated α-synuclein. Tissue slices were prepared exactly as
described for similar studies using AD tissue as a source of
physiologically aggregated Aβ [10,12]. All tissue was
obtained from patients who died with Lewy body disease
and who volunteered to donate brain tissue to the Neu-
ropathology Core of the Alzheimer Disease Research
Center at the University of Washington. All tissue was cry-
ostat sectioned into 10 μm thick slices, mounted onto
poly-D-lysine-coated coverslips, and placed in 24-well tis-
sue culture plates as previously described by us and others
[10,12].
EP2-/- mice are a gift from Dr. Richard Breyer at Vanderbilt
University Medical Center (Nashville, TN). Mice
homozygous for disruption of the gene that encodes
EP2(EP2-/-) were backcrossed >12 generations to the
BALB/c genetic background [13]. Age-matched BALB/c
wild-type (WT) control mice were obtained from Charles
River Laboratories (Wilmington, MA). Mice were main-
tained in a temperature-controlled specific pathogen-free
(SPF) facility with a strict 12-hour light/dark cycle and
with free access to food and water. All experiments were
performed exactly as approved by the University of Wash-
ington Institutional Animal Care and Use Committee
(IACUC).
Primary microglia were isolated as described previously
[9,14]. Briefly, microglia at 14th day in vitro (DIV) were
separated from the underlying astrocytic monolayer by
gentle agitation using their differential adhesive proper-
ties and were seeded onto 10 micron mesocortical sec-
tions set in 24-well plates (described above) at 1 × 105
cells per section in microglial culture medium for 2 hr fol-
lowed by an additional 48 hr incubation in serum-free
DMEM containing penicillin and streptomycin. Follow-
ing incubation, the contents of each well (microglia plus
human tissue) was either lysed with 8 M urea and Western
blotted for remaining α-synuclein aggregates, or fixed for
immunohistochemical studies to visualize activated
microglia and α-synuclein aggregates. For immunohisto-
chemical analysis, fixed cultures (with 4% paraformalde-
hyde in PBS) were subjected to formic acid (88%)
treatment prior to application of antibodies against
CD11b (1:50) and anti-α-synuclein (1:200). Mounting
medium containing DAPI was used to label the nuclei. Of
note, to minimize the variation among sections used for
WT and EP2-/- microglia (see below), consecutive sections
were selected.
In vivo studies
For chronic MPTP treatment, 8- to 10-wks WT and EP2-/-
Balb/C mice, weighing 18–22 g at the beginning of theJournal of Neuroinflammation 2007, 4:2 http://www.jneuroinflammation.com/content/4/1/2
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study, were rendered parkinsonian with a protocol previ-
ously used by us [15]. Briefly, mice were treated with 10
doses of MPTP hydrochloride (25 mg/kg in saline, s.c.)
and the adjuvant probenecid (250 mg/kg in DMSO, i.p.)
on a five-week schedule with an interval of 3.5 days
between consecutive doses. Probenecid was used to
inhibit the rapid clearance and excretion of MPTP from
the brain and kidney following each injection. Control
groups were treated with probenecid alone. Five weeks
after the last treatment, the brains were rapidly removed
and blocked sagittally with half fixed in freshly prepared
paraformaldehyde and the other half dissected and stored
at -70°C until assayed. DA concentration in each animal
were quantified using HPLC-EC as described previously
[15]. For sub-chronic MPTP treatment, mice received
MPTP hydrochloride (30 mg/kg in saline, s.c.) once a day
for 5 consecutive days; the animals were sacrificed five
days after the last injection to measure striatal DA [16].
The method for fractionation of α-synuclein aggregates
was described in our previous study [17]. Frozen mouse
substantia nigra (SN) and striatum were homogenized in
a NP40 lysis buffer containing 0.5% NP-40, 150 mM
NaCl, 50 mM Tris, pH 8.0, 700 U/ml DNase I, and pro-
tease inhibitor cocktail. One small aliquot of cell lysate
was removed for later total protein determination using
the BCA assay (Pierce, Rockford, IL). An equal amount of
homogenate was centrifuged at 10,000 × g for 10 min to
yield a NP-40 soluble fraction and a pellet. The pellet was
re-suspended in sodium dodecyl sulfate (SDS) buffer (2%
SDS, 62.5 mM Tris, pH 6.8, 10% glycerol) and incubated
at room temperature for 30 min with constant agitation.
The extract was then centrifuged at 14,000 × g for 10 min
at 4°C to generate an SDS-soluble (NP40-insoluble) frac-
tion. Distribution of protein aggregates was compared in
various experimental conditions between the two frac-
tions by Western blot analysis.
In vitro studies
To generate in vitro aggregated  α-synuclein, purified
human α-synuclein (1 mg/mL) was incubated in PBS at
37°C with constant agitation using a magnetic stir bar in
1.7 mL Eppendorf tubes. The resultant α-synuclein spe-
cies, predominantly oligomers, are almost identical to
those obtained by aging in vitro for 7 days without stirring
[9]. Microglia (see above) were seeded in six-well plates at
1–2 × 106 cells per well in microglial culture medium,
incubated overnight, and then exposed to in vitro aggre-
gated α-synuclein for 30 min. After treatment, cells were
washed twice with ice-cold PBS and then scraped off in a
non-detergent homogenization buffer (250 mM sucrose,
10 mM Tris-HCl (pH7.8), 5 mM MgCl2, 2 mM EGTA, 2
mM EDTA, and protease inhibitor cocktail (1 mM PMSF).
The cell lysate was centrifuged at 1000 × g for 10 min to
remove cell debris and crude nuclei. Protein concentra-
tion of supernatant was measured by BCA assay. An equal
amount of supernatant was further centrifuged at 55,000
rpm (Optima™ MAX benchtop ultracentrifuge, Beckman
Coulter, Fullerton, CA) for 90 minutes to separate into
cytoplasm (supernatant) and membrane (pellet) frac-
tions. The pellets were resuspended in SDS lysis buffer
(2% SDS, 62.5 mM Tris, pH 6.8, and 10% glycerol) in
preparation for Western blotting to assess translocation of
NADPH subunits (p47 and p67).
Western blot
An equal volume of proteins from buffer- and SDS-solu-
ble fractions (for analysis of α-synuclein aggregates distri-
bution in mouse brain tissue) or from cytoplasm and
membrane fractions (for analysis of NADPH subunits
translocation) were diluted 1:2 in 2× loading buffer con-
taining 5% β-mercaptoethanol and heated to 95°C for 10
min before loading onto 8–16% SDS polyacrylamide gels.
Following separation, the proteins were transferred to
PVDF membranes (Bio-Rad Laboratories, Hercules, CA),
and probed overnight at 4°C with polyclonal rabbit anti-
α-synuclein (1:5000) or p47-phox/p67-phox (1:1000)
primary antibodies. After washing with TBST (0.1%
Tween-20 in TBS), goat anti-rabbit-HRP secondary anti-
body was added at 1:40,000 for 1 h at room temperature,
and detection was carried out by enhanced chemilumi-
nescence. The relative intensity of the corresponding
bands was quantified with Quantity One (Bio-Rad).
Statistical methods
Repeated measures were performed at least three times in
all experiments. Grouped data were expressed as mean ±
S.E.M. Changes between two groups were analyzed by t-
test or two-way analysis of variance (ANOVA), depending
on the experiments, using a commercially available com-
puter software program (Prism 3.0; GraphPad, San Diego,
CA) with α = 0.05.
Results
EP2-/- microglia enhanced the clearance of α-synuclein 
aggregates in the mesocortex of patients with Lewy body 
disease
We have previously demonstrated that microglia lacking
EP2 show enhanced phagocytosis of Aβ aggregates while
at the same time display suppressed bystander damage to
neurons [10]. Using the technique of Bard et al. [12] in
that study we incubated mouse microglial cultures with
10 micron tissue slices of human AD brain as a source of
physiologically aggregated Aβ. To test whether these
results can be extended to α-synuclein aggregates, we used
a similar human ex vivo model. Primary microglia from
either EP2-/- or WT mice were incubated with mesocortical
sections of patients with Lewy body disease as a source of
physiologically aggregated α-syuclein oligomers for 48
hrs, followed by quantification of residual α-synucleinJournal of Neuroinflammation 2007, 4:2 http://www.jneuroinflammation.com/content/4/1/2
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oligomers by Western blot analysis. The distribution and
morphology of microglia in each experiment were also
assessed microscopically after immunohistochemical
staining against CD11b, a marker for activated microglia.
Our results demonstrated that the level of α-synuclein oli-
gomers was less in sections incubated with EP2-/- micro-
glia compared to consecutive sections incubated with WT
microglia. A representative Western blot is shown in Fig-
ure 1A. Quantitative assessment (Figure 1B) indicated that
the residual α-synuclein oligomers in the sections incu-
bated with EP2-/- microglia was approximately 70% of
that incubated with WT microglia (P < 0.05; n = 6). A rep-
resentative section incubated with EP2-/-  microglia is
shown in Figure 1C, where activated microglia were iden-
tified in close proximity to aggregated α-synuclein.
EP2-/- mice were more resistant to neurotoxicity induced by 
MPTP
Given that microglia from EP2-/- mice exhibited enhanced
capacity to clear aggregated α-synuclein from human tis-
sue, we next investigated the effects of ablation of EP2-/-
on nigrostriatal neurodegeneration induced by the par-
kinsonian toxicant MPTP using a chronic regimen that
was established in our lab recently. In this model, EP2-/-
and WT mice were treated with MPTP at 25 mg/kg along
with an adjuvant (probenecid), at 250 mg/kg for 5 weeks.
Five weeks after the last treatment, the residual striatal DA
level in each mouse was determined as an index of the
extent of nigrostriatal damage. We found that there was
no significant difference in DA levels in WT and EP2-/-
mice without MPTP treatment (P > 0.05, data not shown).
The remaining striatal DA level in WT mice treated with
MPTP was reduced to 32 ± 2% of the level in vehicle-
treated WT mice (Figure 2A), similar to our previous
results [15]. In contrast, the remaining striatal DA level in
EP2-/- mice treated with MPTP was 56 ± 2% of the level in
vehicle-treated EP2-/- mice (Figure 2A). We also tested
whether ablating EP2-/- had any effect in a sub-chronic
model, where mice were treated with MPTP at 30 mg/kg
per day for five days, and the extent of nigrostriatal degen-
eration was assessed five days after the last injection. It is
remarkable that this sub-chronic model largely recapitu-
lated what was observed in mice treated with MPTP
chronically. In fact, the residual DA level was not signifi-
cantly different between EP2-/- mice treated with MPTP
Lack of EP2 enhanced microglial clearance of α-synuclein aggregates Figure 1
Lack of EP2 enhanced microglial clearance of α-synuclein aggregates. A and B). Tissue sections obtained from 
patients with dementia with Lewy body disease were incubated with WT and EP2-/- microglia for 48 hrs. Residual α-synuclein 
aggregates were determined by Western blotting (two bands corresponding to dimers and trimers of α-synuclein). *: p < 0.05 
for amount of residual synuclein aggregates in tissue sections treated with EP2-/- vs. WT microglia. C) Tissue sections were 
stained with CD11b antibody 48 hrs after incubation with microglia. The image demonstrates an activated microglial cell in ex 
vivo-cultured slides in close proximity to aggregated α-synuclein. Red, CD11b for microglia showing a macrophage-like micro-
glia; green, antibody against human α-synuclein, demonstrating α-synuclein aggregates; and blue, DAPI nuclear staining).
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and those treated with vehicle, while WT mice lost > 75%
of their striatal DA after MPTP treatment.
Attenuated formation of NP-40 insoluble α-synuclein 
aggregates in EP2-/- mice
Reduced neurotoxicity in EP2-/- mice exposed to MPTP
could derive from several possible mechanisms. As α-
synuclein aggregation plays critical roles in neurodegener-
ation in human PD as well as parkinsonian animals, we
next tested the hypothesis that EP2-/- mice had altered
accumulation of detergent-soluble α-synuclein oligomers,
precursors of insoluble α-synuclein fibrils and the puta-
tive major neurotoxic species of α-synuclein [18]. We
focused on the chronic MPTP model as previous experi-
ments have demonstrated that Lewy body-like inclusions
can be induced in this model at later time points [15,19].
Both the substantia nigra (SN) and striatum were dis-
sected and extracted into NP40-soluble and NP40-insolu-
ble/SDS-soluble fractions. We determined by Western
blot the relative distribution of α-synuclein aggregates
between theses two fractions, expressed as percent of
detergent-soluble α-synuclein aggregates (from both frac-
tions) in the NP40-insoluble fraction (Figure 3). Several
observations were made: 1) there was no significant dif-
ference in basal (vehicle-treated) distribution of α-synu-
clein aggregates between EP2-/- and WT mice, whether in
the SN or striatum; 2) the shift in distribution of deter-
gent-soluble α-synuclein aggregates (from NP40-soluble
to NP40-insoluble) in WT mice was statistically signifi-
cant at five weeks post-MPTP treatment in the SN but not
in the striatum; and 3) in contrast to WT mice, in EP2-/-
mice there was no significant change in the distribution of
detergent-soluble α-synuclein aggregates between the two
fractions in either the SN or striatum following MPTP
treatment.
Attenuated translocation of PHOX p47 subunit from 
cytoplasm to membrane in EP2-/- microglia treated with α-
synuclein oligomers
Given our previous findings with EP2-/- microglia and
microglia-mediated bystander damage to neurons,
another possible explanation for suppressed neurotoxicity
in MPTP- exposed mice was reduced activation of neuro-
toxic components of the microglia response. Indeed, our
previous experiments have demonstrated that extracellu-
lar aggregated α-synuclein potently activates microglia,
leading to activation of PHOX (NADPH oxidase) and
enhanced DAergic neurotoxicity [9]. PHOX activation
involves translocation of several critical cytoplasmic units
to the membrane compartment; thus, we next investi-
gated whether ablation of the EP2-/- receptor had any
effects on two of these subunits, p67-phox and p47-phox.
Microglia were isolated from WT and EP2-/- mice, respec-
tively, and seeded in 6-well plates overnight and then
treated with pre-aged α-synuclein or vehicle for 30 min.
The cells were then homogenized and fractionated into
cytoplasmic and membrane fractions, and the fractions
Western blotted. Translocation of p67-phox and p47-
phox was analyzed by determining changes in their rela-
tive levels in the cytoplasmic and membrane fractions fol-
lowing exposure to aggregated α-synuclein. The results,
presented in Figure 4, show that aggregated α-synuclein
Lack of EP2 suppressed loss of striatal dopamine in MPTP-treated mice Figure 2
Lack of EP2 suppressed loss of striatal dopamine in MPTP-treated mice. Mice were treated with either a chronic 
(panel A) or sub-chronic regimen of MPTP (panel B). In the chronic protocol, mice were treated with MPTP (30 mg/kg × 10) 
and the adjuvant probenecid (250 mg/kg) on a five-week schedule with an interval of 3.5 days between consecutive doses. In 
the sub-chronic model, mice were treated with MPTP (30 mg/kg*day) or vehicle for five days. Remaining DA in the striatum of 
mice was measured by HPLC 5 weeks or 5 days post-final treatment in the chronic and subchronic models, respectively. Data 
are expressed as % control where control mice were the corresponding genotype treated with vehicle. *, **: p < 0.05 and p < 
0.01 comparing EP2-/- with WT mice, respectively.
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led to translocation of both subunits to membrane in WT
glia. Intriguingly, while there was no significant difference
in the translocation of p67-phox subunit (Figure 4A)
between the two types of microglia, translocation of the
p47-phox subunit appeared to be attenuated in EP2-/-
microglia treated with aged α-synuclein compared to WT
controls. More specifically, approximately 50% of p47-
phox was shifted into the membrane compartment in WT
treated with aged α-synuclein, compared to approxi-
mately 30% of this subunit in EP2-/- microglia (n = 5, p <
0.05).
Discussion
Several major observations were made in this study,
including: 1) microglia isolated from EP2-/-  microglia
exhibited enhanced clearance of aggregated α-synuclein
from the tissue sections of patients with Lewy body dis-
ease; 2) mice without EP2 were more resistant to neuro-
toxicity induced by MPTP, and this effect was seen in
association with attenuated formation of aggregated α-
synuclein in the SN and striatum; and 3) EP2-/- microglia
exposed to aggregated α-synuclein appeared to have less
membranous translocation of p47-phox, a critical process
leading to PHOX activation.
The observation that EP2-/-  mice had significantly
increased ability in clearing aggregated α-synuclein from
human tissue with Lewy body disease is identical to the
observation made earlier by our group, where EP2-/-
microglia cleared aggregated Aβ [10] more effectively than
WT microglia in human hippocampal slices. Although the
precise mechanisms underlining the enhanced phagocy-
tosis in EP2-/- microglia remain to be defined, this obser-
vation is quite significant. This is because we have recently
observed that aggregated α-synuclein activates microglia
efficiently, leading to enhanced DAergic neurotoxicity [9].
It should also be noted that α-synuclein can be actively
secreted by neurons to extracellular space where it aggre-
gates faster [20]. Finally, our ongoing study has further
illustrated that internalization of aggregated α-synuclein
is not necessary for aggregated α-synuclein to activate
microglia (not shown), meaning that increased phagocy-
tosis does not necessarily translate into increased micro-
glial activation with production of neurotoxic species
[21,22]. On the other hand, activated microglia may pro-
duce neuroprotective factors [23], i.e. the final outcome of
microglial activation may depend on the delicate balance
between these two forces [24]. To this end, subtypes of
PGE2 receptors may play a major role. This is because
PGE2 can interact with four distinct receptor subtypes:
EP1, EP2, EP3 and EP4, that are linked to functionally
antagonistic second messenger systems [25]. For instance,
EP1 increases intracellular concentration of calcium; EP2
and EP4 activate adenylyl cyclase via stimulatory GTP-
binding proteins, while EP3  mainly inhibits adenylyl
cyclase via inhibitory GTP-binding proteins [26]. All EP
Lack of EP2 attenuated formation of NP40-insoluble α-synuclein aggregates in both SN and striatum Figure 3
Lack of EP2 attenuated formation of NP40-insoluble α-synuclein aggregates in both SN and striatum. SN and 
striatum were dissected at 5 weeks after the last treatment and fractionated into NP40-soluble and NP40-insoluble/SDS-solu-
ble fractions, followed by assessment by Western blot. Data is expressed as NP-40 insoluble (SDS-soluble) α-synuclein aggre-
gates as a fraction of total (NP40- and SDS-) soluble α-synuclein. *: p < 0.05 comparing WT-MPTP vs. WT-control (con) and 
EP2-/--MPTP vs. WT-MPTP, respectively, in the SN. **: p < 0.01 comparing EP2-/--MPTP vs. WT-MPTP in the striatum (n = 8).
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receptor subtypes are expressed on varying cells in the
brain and it has been demonstrated that microglia express
both EP1 and EP2 [27].
It is possible that ablating EP2 may have indirect effects
on phagocytosis through compensatory up-regulation of
other EP receptors on microglia. Ideally, a direct effect of
Lack of EP2 reduced translocation of p47-phox but not p67-phox subunit from cytoplasm to membrane in microglia after α- synuclein oligomer treatment Figure 4
Lack of EP2 reduced translocation of p47-phox but not p67-phox subunit from cytoplasm to membrane in 
microglia after α-synuclein oligomer treatment. WT or EP2-/- microglia were seeded in 6-well plates overnight and 
then treated with aged α-synuclein or vehicle for 30 min. The cells were homogenized and fractionated into cytoplasm (cyt) 
and membrane fractions (mem). The relative distribution of p67-phox (panel A) and p47-phox (panel B) in the two fractions 
was analyzed with Western blot in order to assess translocation from the cytoplasm to the membrane (expressed as ratio of 
relative amount in membrane fraction to membrane + cytoplasm). *: p < 0.05, comparing EP2-/- with WT microglia. **: P < 
0.01, comparing α-synuclein treatment with control.
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EP2 on phagocytosis could be evaluated by restoring EP2
function in cultured EP2-/- microglia. While the EP2 ago-
nist butaprost (or CAY10399) has been a valuable tool for
distinguishing EP2-specific activity [28-30], it unfortu-
nately is of limited use in characterizing EP2-/- cells, since
it does not restore EP2 function in the absence of the
receptor. Indeed, negative results following butaprost
exposure in EP2-/- mice have been used to identify EP2-
specific effects, since butaprost does not bind appreciably
to any of the other EP receptors [29]. For instance,
Kennedy et al. demonstrated that while butaprost infu-
sion has a significant effect on blood pressure in wt mice,
no response is seen in EP2-/- mice, while a prostacyclin
receptor antagonist elicits a similar response in both [13].
In our MPTP model, when mice were treated with either
subchronic or chronic regimen, the data clearly showed
that mice without EP2 had greater striatal DA levels, the
loss of which is a widely accepted marker of toxicity to DA
neurons. More importantly, EP2-/-  mice also demon-
strated less NP40-insoluble aggregated α-synuclein in
both SN and striatum. As abundant evidence has sug-
gested that aggregated α-synuclein is toxic to neurons, it is
reasonable to suggest that the mechanisms by which EP2-
/- mice became more resistant to MPTP were at least par-
tially attributable to their enhanced ability to either pre-
vent the formation of or better clear aggregated α-
synuclein by microglia. That being said, mechanisms
other than aggregated α-synuclein may be involved in
DAergic neurodegeneration, which may or may not relate
to α-synuclein aggregation directly. These may include:
mitochondrial inhibition [31], increased oxidative stress
[32], and decreased proteasomal and lysosomal functions
[33,34]. This issue is further complicated by the fact that
EP2 is also expressed in cells other than microglia [35],
raising the possibility that protective effects seen in EP2-/-
may be related to factors involving other cells. Nonethe-
less, the fact that microglia derived from EP2-/-  mice
clearly showed increased capacity in the clearance of both
Aβ and α-synuclein without increasing microglial para-
crine neurotoxicity strongly emphasizes the role of EP2 in
neurodegeneration in both AD and PD.
With respect to the mechanisms underlying microglial
activation induced by α-synuclein aggregates, our in vitro
data unequivocally showed that EP2-/- microglia had less
translocation of p47-phox subunit of PHOX after expo-
sure to aggregated α-synuclein. It is known that α-synu-
clein is intimately associated with increased ROS
production by PHOX activation [9] and that PHOX is a
membrane-associated enzyme that generates O2
- by cata-
lyzing the transfer of electrons from NADPH to molecular
oxygen. The production of O2
-  was also measured in
microglia generated from both EP2-/- and BALB/c mice
after treatment with aggregated α-synuclein (not shown).
While we have measured O2
- in C57Bl/6 mice [9], in Balb/
C mice the results were inconclusive as basal levels of O2
-
were highly variable; a definitive result would have
strengthened our interpretation of the p47 translocation
data. Nonetheless, since translocation of several cytoplas-
mic subunits to the membranous compartment is critical
to microglial activation [36,37], it is expected that ROS
production in EP2-/- microglia should also be attenuated
as compared to WT controls after exposure to aggregated
α-synuclein. Increasing evidence has indicated that p47-
phox plays a central role in the assembly process of
PHOX, possibly by sensing the activation signal through
multiple phosphorylations and then acting as a scaffold-
ing protein for translocation and assembly of the subunits
of PHOX [38]. What remains to be studied is: why was the
translocation of p47-phox, but not p67-phox, affected by
ablating EP2 receptor? To this end, one of the potential
fruitful areas in the further research could be cAMP-
dependent signal transduction pathways. This is because
many investigators have demonstrated that EP2 regulates
the intracellular levels of cAMP [25,39,40], which has a
significant (and controversial) effects on the transloca-
tion/activation of PHOX [41-43].
Conclusion
In summary, we have tested our hypothesis that the EP2
receptor is critical in regulating aggregated α-synuclein
levels in PD, thereby influencing neurodegeneration
induced by aggregated α-synuclein via ex-vivo, in vivo and
in vitro studies, respectively. Our results demonstrated that
EP2-/- microglia exhibited enhanced capacity in clearing
aggregated α-synuclein in human mesocortex tissue with
Lewy body disease. In addition, EP2-/-, while exhibiting
less aggregated α-synuclein, were also more resistant to
neurotoxicity induced MPTP. Finally, EP2-/-  microglia
appeared to have less translocation of a critical cytoplas-
mic subunit (p-47-phox) of PHOX to the membranous
compartment after exposure to aggregated α-synuclein.
Further characterization of the role of EP2 receptor could
lead to better understanding of the pathophysiology
involved in synucleinopathy as well as the development
of novel therapeutic targets that enhance microglial
phagocytosis of α-synuclein aggregates while also sup-
pressing microglia-mediated neurotoxicity.
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